Dr. Rory Michael Shallis, MD

Dr. Shallis practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Shallis' NPI, 1669884383, was assigned on May 29, 2014. Dr. Shallis graduated from Rutgers Robert Wood Johnson Medical School in 2014. Dr. Shallis holds Florida license ME171810.

Dr. Shallis' primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Shallis' primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dr. Shallis is also affiliated with Yale New Haven Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Shallis to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shallis practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shallis' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shallis is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Shallis' licenses on file in 3 states: Florida, Connecticut and Rhode Island.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Shallis treats.

CMS data shows 524 Medicare services from Dr. Shallis across 8 procedure codes in 2024, for 116 Medicare patients. Medicare paid $36,152 for them.

CMS counts 116 Medicare patients who saw Dr. Shallis in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 3.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shallis' median patient age at 70, with 44% women.

In 2024, Dr. Shallis wrote 403 Medicare Part D claims for 75 patients. 51% of them were for generic drugs. CMS names the drug for 296 of them, across 13 drugs with 11 or more claims each, at $2,030,703 in total drug cost. In 2023, CMS named 231 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Shallis for performance year 2024, reported as part of a group. Dr. Shallis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shallis as offering telehealth.

Dmand AI links 10 papers to Dr. Shallis, published from 2015 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Myelodysplastic Syndromes, Antineoplastic Agents and Molecular Targeted Therapy. Dr. Shallis has published most often in Clin Lymphoma Myeloma Leuk. Dr. Shallis' most frequent co-authors are Jan Philipp Bewersdorf, MD, Amer Zeidan and Ehab L. Atallah, MD.

CMS Open Payments shows 54 general payments to Dr. Shallis from 10 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 68% of the total. Servier Pharmaceuticals LLC paid the most, $9,644.

Dr. Shallis graduated from Rutgers Robert Wood Johnson Medical School in 2014.

Dr. Shallis is in network with 12 carriers, including Elevance, Aetna and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.